Nikko Asset Management Americas Inc. acquired a new stake in Codexis, Inc. (NASDAQ:CDXS) in the 1st quarter, according to the company in its most recent filing with the SEC. The fund acquired 340,262 shares of the biotechnology company’s stock, valued at approximately $6,986,000. Nikko Asset Management Americas Inc. owned approximately 0.63% of Codexis as of its most recent SEC filing.
Other large investors also recently added to or reduced their stakes in the company. Quantamental Technologies LLC bought a new stake in Codexis during the 4th quarter valued at $26,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Codexis by 152.0% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,837 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 1,711 shares in the last quarter. Legal & General Group Plc increased its stake in Codexis by 12.1% during the 4th quarter. Legal & General Group Plc now owns 9,379 shares of the biotechnology company’s stock valued at $157,000 after purchasing an additional 1,010 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its stake in Codexis by 13.3% during the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $207,000 after purchasing an additional 1,186 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC bought a new stake in Codexis during the 4th quarter valued at $217,000. Institutional investors own 85.12% of the company’s stock.
CDXS traded up $0.42 during mid-day trading on Friday, reaching $19.16. 170,900 shares of the stock were exchanged, compared to its average volume of 385,491. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.42 and a quick ratio of 3.38. The company has a market capitalization of $1.04 billion, a price-to-earnings ratio of -91.24 and a beta of -0.37. Codexis, Inc. has a 1 year low of $12.85 and a 1 year high of $23.05.
Codexis (NASDAQ:CDXS) last posted its quarterly earnings data on Monday, May 6th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.09). The firm had revenue of $15.58 million for the quarter, compared to the consensus estimate of $14.83 million. Codexis had a negative net margin of 18.22% and a negative return on equity of 21.08%. As a group, equities analysts anticipate that Codexis, Inc. will post -0.23 EPS for the current year.
A number of brokerages have commented on CDXS. Craig Hallum boosted their price target on shares of Codexis from $20.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, February 27th. ValuEngine upgraded shares of Codexis from a “buy” rating to a “strong-buy” rating in a research note on Monday, April 1st. BidaskClub upgraded shares of Codexis from a “hold” rating to a “buy” rating in a research note on Monday, April 1st. HC Wainwright boosted their price target on shares of Codexis to $22.50 and gave the company a “buy” rating in a research note on Monday, March 4th. Finally, Zacks Investment Research lowered shares of Codexis from a “hold” rating to a “sell” rating in a research note on Friday, May 10th. One investment analyst has rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Codexis has a consensus rating of “Buy” and a consensus price target of $21.07.
In other Codexis news, SVP James Lalonde sold 19,999 shares of Codexis stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $18.65, for a total transaction of $372,981.35. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Gordon Sangster sold 80,000 shares of Codexis stock in a transaction on Thursday, March 21st. The stock was sold at an average price of $20.88, for a total transaction of $1,670,400.00. Following the transaction, the chief financial officer now directly owns 174,453 shares in the company, valued at $3,642,578.64. The disclosure for this sale can be found here. Insiders have sold a total of 164,071 shares of company stock worth $3,388,171 over the last ninety days. Insiders own 10.70% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was first published by Sundance Herald and is the sole property of of Sundance Herald. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://sundanceherald.com/2019/05/24/340262-shares-in-codexis-inc-cdxs-purchased-by-nikko-asset-management-americas-inc.html.
Codexis, Inc discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services.
Featured Story: What is the Dividend Aristocrat Index?
Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.